Assessing Recurrence Risk in Early-Stage Triple-Negative Breast Cancer

Priya Rastogi, MD, discusses a substudy evaluating a whole-exome sequencing, tumor-informed ctDNA MRD assay in TNBC after neoadjuvant chemotherapy.

Ruta D. Rao, MD, discusses a prospective sub-study of the PARTNER trial evaluating the effect of ctDNA status on distant recurrence in early TNBC.

Priya Rastogi, MD, discusses findings from a sub-study of the GeparDouze trial evaluating the effects of ctDNA positivity on treatment outcomes in TNBC.

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.